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Abstract. We have identified a novel peroxisomal tar- 
geting sequence (PTS) at the extreme COOH terminus 
of human catalase. The last four amino acids of this 
protein (-KANL) are necessary and sufficient to effect 
targeting to peroxisomes in both human fibroblasts and 
Saccharomyces cerevisiae,  when appended to the 
COOH terminus of the reporter protein, chloram- 
phenicol acetyl transferase. However, this PTS differs 
from the extensive family of COOH-terminal PTS tri- 
peptides collectively  termed PTS1 in two major aspects. 
First, the presence of the uncharged amino acid, aspar- 
agine, at the penultimate residue of the human catalase 
PTS is highly unusual, in that a basic residue at this po- 
sition has been previously found to be a common and 
critical feature of PTS1 signals. Nonetheless, this aspar- 
agine residue appears to constitute an important com- 
ponent of the catalase PTS, in that replacement with as- 
partate abolished peroxisomal targeting (as did 
deletion of the COOH-terminal four residues). Second, 
the human catalase PTS comprises more than the 
COOH-terminal three amino acids, in that COOH-ter- 
minal - ANL cannot functionally replace the PTS1 sig- 
nal -SKL in targeting a chloramphenicol acetyl trans- 
ferase fusion protein to peroxisomes. The critical 
nature of the fourth residue from the COOH terminus 
of the catalase PTS (lysine) is emphasized by the fact 
that substitution of this residue with a variety of other 
amino acids abolished or reduced peroxisomal target- 
ing. Targeting was not reduced when this lysine was re- 
placed with arginine, suggesting that a basic amino acid 
at this position is required for maximal functional activ- 
ity of this PTS. In spite of these unusual features, hu- 
man catalase is sorted by the PTS1 pathway, both in 
yeast and human cells. Disruption of the PASIO gene 
encoding the S. cerevisiae PTS1 receptor resulted in a 
cytosolic location of chloramphenicol acetyl transferase 
appended with the human catalase PTS, as did expres- 
sion of this protein in cells from a neonatal adrenoleu- 
kodystrophy patient specifically defective in PTS1 im- 
port. Furthermore, through the use of the two-hybrid 
system, it was demonstrated that both the PASIO gene 
product (Pasl0p) and the human PTS1 receptor can 
interact with the COOH-terminal region of human cat- 
alase, but that ithis interaction is abolished by substitu- 
tions at the penultimate residue (asparagine-to- 
aspartate) and at the fourth residue from the COOH 
terminus (lysine-to-glycine) which abolish PTS func- 
tionality. We have found no evidence of additional tar- 
geting information elsewhere in the human catalase 
protein. An internal tripeptide (-SHL-, which conforms 
to the mammalian PTS1 consensus) located nine to 
eleven residues from the COOH terminus has been ex- 
cluded as a functional PTS. Additionally, in contrast to 
the situation for S. cerevisiae catalase A, which contains 
an internal PTS in addition to a COOH-terminal PTS1, 
human catalase lacks such a redundant PTS, as evi- 
denced by the exclusive cytosolic location of human 
catalase mutat+d in the COOH-terminal PTS. Consis- 
tent with this species difference, fusions between cata- 
lase A and human catalase which include the catalase A 
internal PTS are targeted, at least in part, to peroxi- 
somes regardless of whether the COOH-terminal hu- 
man catalase PTS is intact. 
C 
ATALASE (EC 1.11.1.6) is a homotetrameric heme- 
containing enzyme present within the matrix of all 
peroxisomes,  where it is responsible  for degrada- 
tion to water and oxygen of the hydrogen peroxide gener- 
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ated through the action of peroxisomal oxidases  (13, 33, 
62). The fundamental biochemical  importance of this ac- 
tivity is exemplified by the observation that catalase-defi- 
cient yeast cells fail to grow on fatty acid substrates of per- 
oxisomal 13-oxidation, presumably due to accumulation of 
toxic hydrogen peroxide (65, 72). Moreover, the pivotal 
role of catalase in peroxisomal  biology is underscored by 
its assignment as a defining characteristic  of peroxisomes, 
which  otherwise  demonstrate  considerable  variation  in 
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cies (13, 33, 62). 
The biogenesis of catalase exhibits a number of interest- 
ing features. As for all peroxisomal proteins (33), catalase 
is synthesized on cytosolic free polyribosomes (22, 49). In 
rat liver, import of catalase monomers has been shown to 
occur posttranslationally with a half-life of 14 min. After 
import,  addition  of  heme  and  tetramerization  proceed 
within  the  organelle  to  produce  mature  active  catalase 
(32). However, there is considerable evidence that cata- 
lase assembly can also occur outside of the  peroxisome. 
For instance, in both guinea pig liver (71) and yeast cells 
(59, 61), catalase activity is present both in peroxisomes 
and in the cytosol. Furthermore, in cells of patients with 
Zellweger Syndrome, in which catalase (and other peroxi- 
somal matrix proteins) are synthesized normally, but fail 
to be imported across the peroxisomal membrane (34, 62), 
catalase assembles into catalytically active tetramers in the 
cytosol (31, 52, 66, 67). Similarly, in yeast peroxisome bio- 
genesis  mutants,  catalase  A  (normally peroxisomal)  as- 
sembles to its active form in the cytosol (18, 19, 65, 72). 
Recent observations raise the question as to whether per- 
oxisomal catalase is targeted to the organetle exclusively 
as  monomers  (41).  An  investigation  which  used  mono- 
clonal antibodies specific for tetrameric and dimeric/mo- 
homeric catalase subunits concluded that in contrast to the 
situation in rodent liver, human skin fibroblasts assemble 
cytosolic tetrameric catalase within the cytosol (within an 
hour  after synthesis),  which  is  then  targeted  to  peroxi- 
somes for disassembly and import (42). Corroborating evi- 
dence that tetrameric catalase retains import competence 
comes from complementation analysis of Zellweger Syn- 
drome cell lines. These cells can be divided into distinct 
complementation groups such that fusion of cells from dif- 
ferent groups results in appearance within the hybrids of 
catalase-containing peroxisomes (8, 54, 70). In some cases, 
this process is cycloheximide-insensitive, implying that the 
packaged catalase is derived from the assembled cytosolic 
catalase present in the mutants before fusion (9). The ex- 
tensive analysis of catalase targeting in the characteriza- 
tion of cell lines from patients with Zellweger syndrome 
and related disorders provides a clear rationale for deter- 
mination of the catalase PTS, without which the interpre- 
tation of such targeting data is difficult. 
To better understand the biogenesis pathway of peroxi- 
somal catalase, recent effort has been devoted to the iden- 
tification  of  catalase  peroxisomal  targeting  sequences 
(PTSs),  1 through the expression and subcellular localiza- 
tion of various catalase mutants and fusion proteins gener- 
ated by in vitro mutagenesis. Of particular interest is the 
identification of two independent PTSs in catalase A  of 
Saccharomyces cerevisiae, one located internally and the 
other at the COOH terminus (30), and the identification 
of a PTS within the COOH-termina127 residues of human 
catalase (25). These 27 amino acids are of special interest 
in that they terminate with a sequence (-ANL) that falls 
outside the defined consensus for mammalian COOH-ter- 
minal tripeptide PTSs, but do contain an internal tripep- 
1. Abbreviations used in this paper. AGT, alanine:glyoxylate aminotrans- 
ferase; CHAT, chloramphenicol acetyl transferase; PTS, peroxisomal tar- 
geting sequence. 
tide (-SHL-), nine to eleven residues from the COOH ter- 
minus,  which  does conform to this consensus  (25). This 
prompted speculation that tripeptide PTSs might be able 
to function at internal locations in some instances  (25). 
Also of interest is the observation that even though the 
COOH-terminal end of human catalase shows no signifi- 
cant sequence homology to that of yeast catalase A, the 
transgenically  expressed  human  protein  is  targeted  to 
yeast peroxisomes in vivo (14), implying evolutionary con- 
servation of the peroxisomal sorting of this protein. In this 
paper, we address the molecular basis of this conservation 
of targeting by analyzing the sequences within human cat- 
alase responsible for targeting of this protein to yeast and 
human peroxisomes. 
Materials and Methods 
Oligonucleotides 
The sequences of the oligonucleotides used in this study as polymerase 
chain reaction (PCR) primers and for in vitro mutagenesis were as fol- 
lows: C2, 5'-GGCAAGGGAGTAGGCAAATC-3'; C3, 5'-TCCGGAA- 
C'TCAGGTGGCGGCA-3';  C4~  5'-GAGAAGGCAGATC2rGTGAGG- 
3'; C5,'~S--CGGCAAGGGAGG___QGGCAAATCTGTG--A-3';  A1, 5'-AAG- 
ATGTCGAAATTGGGACAAGAA-3'; A2, 5'-GAAAACTCGAGATG- 
CATATGGACA-3'; CH1, 5'-CITGGCGAGATVITCAGGAGC-3' CH2, 
5'-CFAGAGATTCGCCTFCTCCCTI'GCCGCCAACGCCCCGCCCTG- 
3'; CH3, 5'-CTAGAGATTCGCCTTCTCGGCGCCGCCCTG-3'; CH4, 
5'-CTAGAGATTCGCCTTGGCGCCGCCCTG-3';  CH5,  5'-CTAGAG- 
ATrCGCGGCGCCGCCCTG-3';  CH6,  5'-CTAGAGATFCGCI'CCCG 
CCCCGCCCTG-3'; CH7, 5'-CTAGAGC1TCGATCCCGCCCCGCCCTG- 
3';  CH8,  5'-CTAGAGATI'CGCNNNCTCGGCGCCGCCCTG-3'.  C2-C5 
were used for site-directed mutagenesis of the 3' end of the cDNA encod- 
ing human catalase. C2 corresponds to nucleotides 1560-1579 of the hu- 
man catalase cDNA coding sequence (5), and contains a single mismatch 
(underlined) to convert a  lysine codon (AAG) to a  termination codon 
(TAG).  C3  (nucleotides 1543-1563)  contains three mismatches (under- 
lined) to convert the nonanucleotide encoding SHL (TCT CAC TTG) to 
one encoding TQV (ACT CAG GTG). C4 (nucleotides 1567-1586)  con- 
tains  a  single mismatch (underlined)  to  convert  an  asparagine codon 
(AAT) to  an aspartate codon  (GAT).  C5  (nucleotides 1559-1584)  con- 
tains two mismatches (underlined) to convert a lysine codon (AAG) to a 
glycine codon (GGG). 
A1 and A2 were used as PCR primers to amplify the 5' region of the 
yeast catalase A  gene. A1 corresponds to the start of the coding region 
(ATG initiation codon underlined), and A2 is complementary to nucle- 
otides  1124-1143  of the coding sequence (12),  and includes three mis- 
matches (CTAAAT ~  CTCGAG) to introduce an XhoI site (underlined) 
equivalent to that present in the human catalase coding sequence (5). 
CH1 and each of CH2-CH8 were used to amplify the complete coding 
region of the chloramphenicol acetyl transferase gene from the plasmid 
pCAT-Basic (Promega, Madison, WI). CH1  maps from nucleotides -34 
to -  14 relative to the start of the open reading frame. CH2-CH8 are com- 
plementary to the 3' end of the gene, modified to extend the sequence 
by  -LAAREKANL  (CH2),  -EKANL  (CH3),  -KANL  (CH4),  -ANL 
(CH5),  -GANL (CH6),  -GSKL (CH7),  and -EXANL,  where X  is any 
amino acid, or a termination codon (CH8). 
PCR 
One microgram of yeast genomic DNA was subjected to PCR amplifica- 
tion using primers A1 and A2. Amplification buffer consisted of 10 mM 
Tris-HCl (pH 8.3), 50 mM KCI, 1.5 mM MgCI2, 200 ~M dNTPs, and 2 I~M 
of each primer. Samples were heated to 95°C for 5 min before addition of 
2.5  U  of  Taq  Polymerase  (Boehringer  Mannheim  Corp.,  Mannheim, 
FRG). Thirty five cycles of 95°C (90 s), 55°C (60 s), 72°C (120 s), were fol- 
lowed by a final incubation at 72°C for 10 min. For amplification of plas- 
mid pCAT-Basic with primers CH1-CH8, conditions were the same, ex- 
cept that the template was 10 ng plasmid DNA, and the 72°C extension 
time was reduced to 60 s. 
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The plasmids used in this study are shown in Table I. Construction was as 
follows: 
phCATmu  t (for in vitro mutagenesis of human catalase cDNA) was gen- 
erated by subcloning a PstI-PstI fragment containing the complete cata- 
lase  cDNA  coding  region  from pCATI0  (contains full-length catalase 
cDNA [29] in pSP65 vector [Promega]) into the PstI site of pSELECT 
(Promega). 
phCAT1 was constructed by subcloning catalase cDNA from pCAT10 
as a PstI-PstI fragment (see above) into the PstI site of pBluescriptKS(+) 
(Stratagene, La Jolla, CA) to produce a clone with the catalase cDNA on 
a  SalI-SalI fragment, which was then excised and cloned into XhoI di- 
gested pCUP1, such that expression of the human catalase is under the 
control of the copper-sensitive CUP1 promoter (10, 20). 
phCAT2, phCAT3, and phCAT4 were constructed by site-directed mu: 
tagenesis of phCATmut with oligonucleotides C2, C3, and C4, respectively, 
followed  by  replacement  of  the  catalase  cDNA  3'  coding  region  of 
phCAT1  with  the  appropriate  mutated  sequences  using  XhoI  (cuts 
uniquely within the cDNA coding region of phCAT1) and Sacl (cuts 3' to 
the cDNA coding region of phCAT1). 
pCATA-hCAT1  and pCATA-hCAT4  were constructed by replacing 
the 5' regions of phCAT1 and phCAT4, respectively, with the equivalent 
region of the S. cerevisiae catalase A gene, This was achieved by PCR am- 
plifying yeast genomic DNA with primers A1 and A2 (see above) in order 
to  introduce an XhoI  restriction site at  the equivalent position to  the 
unique Xhol site of human catalase cDNA. The PCR product was then 
cloned into pT7Blue (Novagen, Madison, WI), and re-excised as an Accl- 
XhoI fragment, which was then used to replace the ClaI-XhoI fragment 
(which specifies the 5' region of human catalase CDNA) of phCATl and 
phCAT4. 
pChAT-hCAT9 was constructed by cloning the CH1/CH2 PCR prod- 
uct from pCAT-Basic into the Sinai site of pT7Blue, and then subcloning 
(using Sau3A) into pPOX1 (which contains the promoter of yeast acyl Co-A 
oxidase cloned into pRS316 [55]). pChAT-EKANL, pChAT-KANL and 
pChAT-ANL were constructed in exactly the same manner, except using 
CH1/CH3, CH1/CH4, and CH1/CH5 PCR product, respectively. For the 
construction of a series of plasmids identical to pChAT-EKANL, but with 
the lysine residue near the COOH terminus replaced with various other 
residues, the procedure was the same, hut using PCR product generated 
with CH1  and  the degenerate oligonucleotide CH8.  Clones of interest 
were selected by sequencing the pT7Blue recombinants before subcloning 
into pPOX1, pChAT-GANL and pChAT-GSKL were constructed in a 
similar way, except that the CH1/CH6 and CHI/CH7 PCR products from 
pCAT-Basic were cloned into the SmaI site of pRS314 (55), before sub- 
cloning into pPOX1, using EcoRV and BamHI. 
pCMVChAT-GSKL, pCMVChAT-GANL, pCMVChAT-KANL, and 
pCMVChAT-hCAT9  were  constructed  by  subcloning  the  respective 
cloned PCR products into pCMV-link, a vector constructed by the inser- 
tion of the pBluescriptKS(+) polylinker into pCMVI3  (35),  as replace- 
ment for the 13-galactosidase  gene. The cloning enzymes were NotI and 
Kpnl (pCMVChAT-GSKL and pCMVChAT-GANL), and NotI and SpeI 
(pCMVChAT-KANL and pCMVChAT-hCATg). 
pGBT9-hCATI  and pGBT9-hCAT4 were constructed by cloning the 
XhoI-PstI fragments (which encode the COOH-terminal portion of hu- 
man catalase) of phCAT1 and phCAT4, respectively, into pGBT9 (Clon- 
tech Laboratories, Palo Alto, CA) to create in-frame fusions between the 
GAL4 DNA-binding domain and catalase, pGBT9-hCAT1KG was gener- 
ated  by  site-directed mutagenesis of pGBT9-hCAT1  with  primer  C5. 
These  plasmids were  used  as  partners  in  the  two-hybrid system with 
pGAD424-pas10 and pPTS1-BP (21). These latter clones encode the yeast 
PASIO  and  human  PTS1  receptor  genes  cloned  in  pGAD10  and 
pGAD424  (Clontech Laboratories), respectively, to create in-frame fu- 
sions with the GAL4 transactivation domain. 
pCATA-URA3, used for disruption of the catalase A gene from strain 
3A, was constructed by excising the URA3 gene from plasmid pAC100.2 
as an XbaI-XbaI fragment, blunt-ending with Klenow, and inserting into 
the EcoRV site within the catalase A coding region of cloned A1/A2 PCR 
product  (described above  in  the construction  of pCATA-hCAT1  and 
pCATA-hCAT4). 
YeastStrains 
Our laboratory "wild-type" strain 3A (MA Ta, ura3-1, trpl-l, arg4, cttl-l) 
(JW68-3A in [72]) is deficient in cytosolic catalase T, but does contain per- 
oxisomal catalase A. Strain 3A-~CatA (MA Ta, ura3-1, trpl-1, arg4, cttl-1, 
Table I. Plasmids Used in This Study 
Name  Description 
pCAT10 
phCATmut 
phCAT l 
phCAT2 
phCAT3 
phCAT4 
pCATA-hCAT1 
pCATA-hCAT4 
pChAT-hCAT9 
pChAT-EKANL 
pChAT-KANL 
pChAT-ANL 
pChAT-GANL 
pChAT-GSKL 
pChAT-EXANL 
pCMVChAT-hCAT9 
pCMVChAT-GANL 
pCMVChAT-GSKL 
pCMVChAT-KANL 
pGAD424-pas I 0 
pPTS 1  -BP 
pGBT9-hCATI 
pGBT9-hCAT4 
pGBT9-hCAT 1KG 
pCATA-URA3 
Full-length human catalase cDNA cloned into 
EcoRI site of pSP64. 
Complete human catalase eDNA coding sequence 
cloned into pSELECT 
Complete human catalase cDNA coding 
sequence cloned into pCUP1 
phCAT1, mutated to encode catalase lacking the 
COOH- terminal 4 residues 
phCAT1, mutated to encode catalase with 
internal -SHL- changed to -TQV- 
phCAT1, mutated to encode catalase with 
COOH-terminal -ANL changed to -ADL 
phCATI, with region encoding human catalase 
residues 1-383 replaced with the portion of 
S. cerevisiae catalase A gene encoding 
residues 1-378 
phCAT4, with region encoding human catalase 
residues 1-383 replaced with the portion 
of S. cerevisiae  catalase A gene 
encoding residues 1-378 
Chloramphenicol acetyl transferase gene, modified 
to encode an additional nonapeptide corres- 
ponding to the human catalase COOH terminus, 
under control of the promoter of the S. cerevisiae 
POXI gene, cloned into pRS316. 
pChAT-hCAT9, but with the COOH-terminal non- 
apeptide replaced with -EKANL 
pChAT-hCAT9, but with the COOH-terminal non- 
apeptide replaced with -KANL 
pChAT-hCAT9, but with the COOH-terminal non- 
apeptide replaced with -ANL 
pChAT-hCAT9, but with the COOH-terminal non- 
apeptide replaced with -GANL 
pChAT-hCAT9, but with the COOH-terminal non- 
apeptide replaced with -GSKL 
pChAT-hCAT9, but with the COOH-terminal non- 
apeptide replaced with -EXANL, 
where X is one of several different amino acids 
Chloramphenicol acetyl transferase gene, modified 
to encode an additional nonapeptide corres- 
ponding to the human catalase COOH- terminus, 
under control of the CMV promoter in a human 
expression vector based on pCMVI3. 
pCMVChAT-hCAT9, but with the COOH-terminal 
nonapeptide replaced with -GANL 
pCMVChAT-hCAT9, but with the COOH-terminal 
nonapeptide replaced with -GSKL 
pCMVChAT-hCAT9, but with the COOH-terminal 
nonapeptide replaced with -KANL 
GAL4 activation domain fused to Pus 10p, under 
control of ADH promoter. 
GALA activation domain fused to amino acids 
258-639 of human PTS 1 receptor, under 
control of ADH promoter (from Dr. M. Fransen). 
GALA DNA-binding domain fused to residues 
382-527 of normal human catalase, under 
control of ADH promoter. 
pGBT9-hCAT 1, but with COOH- terminus of 
fusion protein mutated to -KADL. 
pGBT9-hCAT1, but with COOH- terminus of fusion 
protein mutated to -GANL. 
URA3 gene cloned within catalase A coding region. 
For catalase A disruption. 
Purdue and Lazarow Catalase Peroxisomal Targeting Sequence  851 ctal::URA3),  which is deficient in both catalase A  and catalase T, was 
constructed by disruption of the catalase A  gene from 3A. This was ef- 
fected by transformation of 3A with KpnI digested pCATA-URA3 fol- 
lowed  by selection  of  Urn  ÷ clones, which were  screened by  immuno- 
fluorescence and  immunoblotting with  anti-catalase  A.  Strain  SFY526 
(MA TcL, his3-200, ade2-101, 1ys2-801, trpl-901, leu2-3, 112, can1, ga14-542, 
ga180-538) (4) contains a GALI-lacz gene fusion suitable for use as a re- 
porter for the two-hybrid system (11).  Strain 3A-ApaslO  (MATa, urn3-1, 
trpl-l,  arg4, cttl-l, paslO::TRP1),  kindly  supplied by  Dr.  J.W.  Zhang 
(Mount Sinai School of Medicine, New York), will be described in detail 
elsewhere. This strain is disrupted at the PASIO locus. 
Yeast Growth Conditions 
For induction of peroxisomes, cells were grown as previously described 
(72),  except  that  preculturing was routinely performed  in SD  medium 
(0.67% yeast nitrogen base, 2% dextrose) supplemented with uracil and 
appropriate amino acids, to maintain selective pressure on plasmids intro- 
duced into the yeast cells, before growth in YPGO medium (1% yeast ex- 
tract, 2 % peptone, 3 % glycerol, 0.1% oleic acid, 0.25 % Tween 40) for 1  g h. 
Expression from the copper-sensitive CUP1 promoter (10, 20) was found 
to be significant in the absence of added copper, and only moderately en- 
hanced by copper addition (48).  Therefore, copper was not added to the 
YPGO for the culturing of cells containing plasmids with the CUP1 pro- 
moter. 
For the two-hybrid system, cells were grown to mid-log phase in SD 
medium supplemented with adenine and appropriate amino acids before 
glass-bead homogenization. 
Transformation and Transfection of  Human Fibroblasts 
Normal human axillary skin fihroblasts, and fibroblasts from a  neonatal 
adrenoleukodystrophy patient (patient A from complementation group 2 
in [44], also referred to as patient PBD018 in [16])  were cultured in Ea- 
gle's minimal essential medium (MEM) supplemented with 10% FCS. For 
transformation, 104 cells were  trypsinized with 0.025%  trypsin in phos- 
phate-buffered saline (PBS), and seeded at a 1:5 dilution into 60-mm petri 
dishes. When subconfluency was reached, cells were washed twice with 
PBS, and incubated with recombinant SV40-Adenovirus (17) for 3 h in se- 
rum-free medium with occasional shaking. Cells were then washed twice 
with PBS and cultured in MEM supplemented with 4%  FCS, with me- 
dium being changed every 3 d. After three weeks, colonies were picked 
and dispersed into MEM with 4% FCS in small petri dishes. Transforma- 
tion was confirmed by morphological changes, proliferative capacity, and 
detection of SV40 large T antigen by immunofluorescence. Calcium phos- 
phate transfection, without DMSO or glycerol shock, was as described (3). 
Immunofluorescence 
lmmunofluorescence analysis  of  YPGO-induced  yeast  cells  was  per- 
formed essentially as described previously (72), with the exception that 
spheroplast formation was performed at 37°C for 15 min in SP buffer (1.2 
M  sorbitol, 20 mM potassium phosphate, pH 7.4) supplemented with 30 
t~g/p.l Zymolyase and 3  l.d/ml  13-mercaptoethanol. Affinity-purified 10- 
330, a polyclonal rabbit antibody against bovine liver catalase which cross- 
reacts with human catalase (51), was used at a dilution of 1:5. Polyclonal 
rabbit  anti-chloramphenicol acetyl  transferase IgG  (5'-3'  Inc.,  Denver, 
CO) and goat antiserum against catalase A  (a kind gift of Dr. Andreas 
Hartig, University of Wien, Wien, Austria) were used at 1:100-1:200. Rab- 
bit antiserum against thiolase (a kind gift of Dr.Wolf Kunau, University of 
Bochum, Bochum, Germany) was used at 1:400. The secondary antibodies 
(Amersham International, UK) were goat anti-rabbit IgG conjugated to 
FITC, used at a dilution of 1:500 (for 10-330, anti-chloramphenicol acetyl 
transferase, and anti-thiolase), and mouse anti-goat IgG  conjugated to 
FITC, used at a dilution of 1:64 (for anti-catalase A). For double immuno- 
fluorescence with anti-chloramphenicol acetyl transferase and anti-cata- 
lase A, a mixture of the primary antibodies at dilutions of 1:100 each was 
applied first, followed by donkey anti-rabbit IgG coupled to FITC (1:50 
dilution) and then, after removal of the secondary antibody and thorough 
washing, rabbit  anti-goat IgG, coupled to TR1TC (1:160  dilution). The 
specificity under these conditions of each of the secondary antibodies was 
confirmed through control  immunofluorescence reactions in which the 
primary antibodies were used separately. 
lmmunofluorescence of transfected fibroblasts was essentially as de- 
scribed previously (51), except that permeabilization was with 1% NP-40 
instead of methanol, and postfixation washes were once in 0.1 M NH4CI in 
PBS, followed by once  in  PBS.  Polyclonal  anti-chloramphenicol acetyl 
transferase was used at a dilution of 1:400. 
lmmunoelectron Microscopy 
Electron microscopic immunolocalization of catalase with gold particles 
was as described by Wright and Rine (69), using polyclonal 10-330 antise- 
rum at a dilution of 1:100, and protein A-gold at 1:50. The size of the gold 
was 20 nm. 
Other Methods 
Standard techniques of molecular biology (3, 50) and yeast genetics (53) 
were used throughout. DNA sequencing, used to confirm the identity of 
various DNA constructs, was by the dideoxy method, with modified T7 
DNA polymerase (Sequenase II, United States Biochem. Corp., Cleve- 
land, OH). In vitro site-directed mutagenesis was performed using the Al- 
tered Sites system (Promega), or the Transformer system (Clontech Labo- 
ratories) as recommended by the manufacturers. Subcellular fractionation 
and glass bead homogenization of yeast cells were as described previously 
(61),  and immunoblotting was performed with the ECL chemilumines- 
cence system (Amersham International), using 1:4,000  dilutions of poly- 
clonal  10-330  serum,  anti-catalase  A  and  anti-chloramphenicol  acetyl 
transferase, and  1:10,000  dilutions of anti-thiolase and anti-~-galaetosi- 
dase. 
Materials 
Anti-l~-galactosidase was from Promega. Plasmids pCAT10, pAC100.2, 
pPTS1-BP, and pGAD424-pas10 were generously supplied by Dr.  Roy 
Gravel  (University  of  Amsterdam),  Dr.  Jeanne  Hirsch  (Mount  Sinai 
School of Medicine, New York), Dr. Marc Fransen (University of Leu- 
yen), and Dr.  Jing-Wei Zhang (Mount Sinai  School of Medicine, New 
York), respectively. Restriction nucleuses and modifying enzymes were 
from Promega or Boehringer Mannheim. 
Results 
Human Catalase Is Targeted to Yeast Peroxisomes 
The ability of yeast peroxisomes to import human catalase 
was  initially assessed  by analysis  of wild-type strain  3A 
(see  Materials  and  Methods)  transformed  with  plasmid 
phCAT1,  which contains normal human  catalase  cDNA 
under  the  regulation of the  copper-sensitive CUP1  pro- 
moter. Immunofluorescence analysis of these cells with af- 
finity-purified polyclonal  10-330  (which  was  previously 
raised against bovine liver catalase, and recognizes human 
catalase [51]) revealed a puncture pattern of human cata- 
lase  distribution  that  was  not  seen  with  untransformed 
cells (Fig. 1). That this reflected peroxisomal targeting of 
the human catalase was verified by immunoelectron mi- 
croscopic analysis of 3A-phCAT1  with  10-330  antibody. 
Labeling with gold particles was effectively  confined to the 
peroxisomal matrix  (Fig.  2 A).  No  other portion of the 
cells was labeled to any significant extent. Differential cen- 
trifugation analysis of this strain demonstrated that most 
of the transgenic human catalase was in the organellar pel- 
let (Fig. 3). These results clearly show that human catalase 
is imported into yeast peroxisomes efficiently. This import 
is independent of the biogenesis of the endogenous yeast 
catalase  A,  since it was  unaffected by disruption  of the 
host 3A catalase A gene (Fig. 3). 
Mutational Strategy 
To determine the sequence(s) of human catalase function- 
ing as  a  peroxisomal targeting sequence (PTS) in  yeast, 
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catalase  (and  variants)  into 
yeast peroxisomes,  as assessed 
by  immunofluorescence.  3A 
cells  were  transformed  with 
plasmids encoding normal  hu- 
man catalase (hCAT; plasmid 
phCAT1),  human  catalase 
with  the COOH-terminal four 
amino  acids deleted  (hCATa4; 
plasmid phCAT2),  human cat- 
alase  with  the  internal-SHL- 
tripeptide  changed  to  -TQV- 
(hCAT.TQV_; plasmid phCAT3), 
and  human  catalase  with  the 
penultimate  residue  changed 
from  asparagine  to  aspartate 
(hCATADL; plasmid  phCAT4). 
Control,  untransformed  3A. 
The primary antibody was poly- 
clonal 10-330, which identifies 
human  catalase,  and  the  sec- 
ondary antibody was goat anti- 
rabbit IgG, coupled to FITC. The variation in intensity  of fluorescence  between cells in this figure, and in Figs. 4, 5, and 7, reflects the 
fact that certain cells lie outside the focal plane, as well as the occasional loss of plasmid from some cells during peroxisome induction on 
YPGO medium. The consistent observation that cells with cytosolic fluorescence appear to give a stronger signal than those with punctate 
fluorescence  (see also Figs. 4 and 5) represents an unexplained  feature of our immunofluorescence  experiments.  It is not due to varia- 
tion in the level of expression of the introduced  plasmid (see immunoblots in Figs. 3 and 4). Bar, 5 I~m. 
various  mutations  were  introduced  into  the  catalase 
cDNA sequence  before expression in  3A cells. Since the 
region of human catalase responsible for peroxisomal tar- 
geting in mammalian cells had previously been suggested 
to  be limited  to  the  COOH-terminal 27  residues  (25), it 
was this region of the protein that was selected for modifi- 
cation. Two tripeptides within this region were of immedi- 
ate interest. One of these was the COOH-terminal tripep- 
tide, which, by analogy with numerous other peroxisomal 
proteins, is a  likely location for a  trI'S. However, the un- 
charged asparagine in the middle of this tripeptide (-ANL) 
excludes it from the defined consensus for PTS activity in 
mammalian cells (S/A/C -  K/R/H -  L), which always has 
a  positively charged amino acid at the  penultimate  posi- 
tion. This heightened interest in the second significant re- 
gion, an internal tripeptide (-SHL-) located nine-to-eleven 
residues from the COOH terminus, which does conform to 
the aforementioned consensus (23). 
Targeting Requires the Extreme 
COOH-Terminal  Sequence 
A  clone encoding catalase with a deletion of the COOH- 
terminal  four  amino  acids  under  the  regulation  of  the 
CUP1  promoter  (phCAT2;  see  Materials  and  Methods 
and Table I) was constructed and transformed into strain 
3A. Immunofluorescence analysis revealed that the trun- 
cated catalase produced from phCAT2 (hCATa4) was dis- 
tributed throughout the cytosol, in contrast to the picture 
seen for normal catalase (Fig.  1). This was confirmed by 
immunoelectron microscopy, which showed an absence of 
peroxisomal  decoration  with  gold,  but  an  apparent  in- 
crease  in  labeling  over the  cytosolic compartment  (data 
similar to Fig. 2 B, not shown). A  virtually identical set of 
results  was  found  for  catalase  that  contained  a  single 
amino  acid  substitution  (asparagine  to  aspartate)  at  the 
penultimate COOH-terminal residue (hCATADL,  encoded 
by plasmid phCAT4). This mutated catalase was found in 
the cytosol by immunofluorescence (Fig. 1). It was missing 
from peroxisomes by immunogold labeling (Fig. 2 B). Fur- 
thermore,  cell  fractionation  analysis confirmed  that  this 
single amino acid substitution effectively abolished target- 
ing of the human catalase to peroxisomes, with only trace 
amounts of hCATADL being found in the organellar pellet, 
in contrast to the efficient import seen in the case of nor- 
mal human catalase (Fig. 3). These results indicate that the 
targeting of human catalase to yeast peroxisomes requires 
the  COOH-terminal  four  amino acids,  and  in  particular 
depends upon the penultimate asparagine residue. 
An Internal SHL Tripeptide Is Not Required 
for Targeting 
To test whether the internal SHL tripeptide plays a role in 
the  peroxisomal targeting  of human  catalase  in  yeast, a 
construct encoding catalase with this tripeptide changed to 
TQV  (hCAT.TQV.,  encoded  by phCAT3)  was generated, 
and then expressed in 3A cells.  Immunofluorescence analy- 
sis of the transformed cells showed that, as for 3A-phCAT1, 
catalase was localized  in  particles  (Fig.  1).  Furthermore, 
immunoelectron microscopy verified that the catalase-pos- 
itive particles were peroxisomes (data  similar to Fig. 2 A, 
not  shown).  These results indicate that the  internal SHL 
tripeptide is not directly involved in peroxisomal targeting. 
The COOH-Terminal  Tetrapeptide of Human Catalase 
Is Sufficient for Targeting a Reporter Protein to 
Peroxisomes, but the COOH-Terminal  Tripeptide Is Not 
A clone (pChAT-hCAT9) encoding chloramphenicol acetyl 
Purdue and Lazarow Catalase Peroxisomal Targeting Sequence  853 Figure 2.  Subcellular localization of various forms of catalase expressed in yeast cells, as assessed by immunoelectron  microscopy.  3A 
cells were transformed with (A) plasmid phCAT1, encoding normal human catalase (hCAT); (B) plasmid phCAT4 encoding human 
catalase with the penultimate residue changed from asparagine to aspartate (hCATADL); (C) plasmid pCATA-hCAT1, encoding a fu- 
sion protein consisting of residues 1-378 of yeast catalase A fused to residues 384-527 of normal human catalase (CATA-hCAT); (D) 
plasmid pCATA-hCAT4, encoding an identical fusion protein to CATA-hCAT, but with the penultimate residue changed from aspar- 
agine to aspartate (CATA-hCATADL).  The inset in C, from a different cell at the same magnification,  is shown to highlight the apparent 
intraperoxisomal aggregation of CATA-hCAT discussed in the text. The antibody was polyclonal 10-330, which identifies human cata- 
lase and the catalase A-human catalase fusion proteins (but not catalase A), followed by protein A-gold. This antibody, which had not 
been affinity-purified, also gives nonspecific labeling of the cell wall. Peroxisomes (P) can be clearly distinguished from mitochondria 
(M) by their single membrane and absence of cristae. Bar, 0.5 tzm. 
The Journal  of Cell Biology, Volume 134, 1996  854 Figure 3.  Immunoblot analysis of subcellular localization of vari- 
ous forms of catalase.  3A and 3A-ACatA were transformed with 
plasmids  encoding  normal  human  catalase  (hCAT;  plasmid 
phCAT1), human catalase with the penultimate residue changed 
from asparagine to aspartate (hCATADL; plasmid phCAT4), a fu- 
sion protein consisting of residues  1-378 of yeast catalase A fused 
to residues  384-527 of normal human catalase (CATA-hCAT; 
plasmid  pCATA-hCAT1),  and  an  identical  fusion  protein  to 
CATA-hCAT, but with  the penultimate residue  changed  from 
asparagine  to  aspartate  (CATA-hCATAoL;  plasmid  pCATA- 
hCAT4).  Postnuclear  supernatant  fractions were separated by 
differential  centrifugation  (61)  into  organeUar  pellets (P), and 
high speed supernatants (S), which were then subjected to SDS- 
PAGE and immunoblotting.  Antibody 10-330 (a-hCAT), which 
recognizes human catalase and the catalase A-human catalase fu- 
sion proteins (but not catalase A), was first used to detect the var- 
ious transgenically  expressed forms of catalase (upper portion of 
figure). After this, the blots were incubated with anti-catalase  A 
(a-CATA), to detect the endogenous catalase A (lower portion 
of figure). 
transferase (CHAT) appended with the last nine amino ac- 
ids of human catalase (-LAAREKANL), under the regu- 
lation of the promoter of POX1 (which encodes peroxiso- 
mal acyl-CoA oxidase), was constructed and expressed in 
3A yeast cells. Immunofluorescence analysis of this strain 
with antibody against ChAT revealed a punctate distribu- 
tion pattern absent from untransformed 3A yeast (Fig. 4 A). 
Cell fractionation showed that the majority of this protein 
was present  in  the  organellar pellet  (Fig.  4  B).  Double- 
immunofluorescence with anti-ChAT and goat anti-catalase 
A  confirmed that the ChAT was targeted to peroxisomes 
(Fig. 4  C). To identify the minimal region within the hu- 
man catalase COOH-terminal nonapeptide  sufficient for 
peroxisomal targeting, a series of related plasmids with de- 
creasing amounts of the human catalase COOH terminus 
appended to ChAT were constructed and expressed in 3A 
cells. This revealed that as few as the COOH-terminal four 
residues (-KANL) were sufficient for targeting to peroxi- 
somes (Fig. 4 A, construct pChAT-KANL). However, fur- 
ther deletion of the lysine residue four amino acids from 
the COOH terminus (construct pChAT-ANL), or substi- 
tution  of  this  lysine  with  glycine  (pChAT-GANL),  re- 
suited in a totally different distribution pattern of CHAT, 
with the vast majority remaining in the cytosol, as assessed 
by both immunofluorescence and cell fractionation (Fig. 4, 
A  and B). The unexpected implication of these results is 
that the  human catalase PTS differs from other  COOH- 
terminal PTSs in that it is defined not by three, but by four 
amino acids.  This is emphasized by the  observation that 
replacement  of the  human  catalase  COOH-terminal  tri- 
peptide of ChAT-GANL with the archetypal PTS1 signal, 
-SKL (to create ChAT-GSKL), restored peroxisomal tar- 
geting  (Fig.  4, A  and  B),  a  result which  is  in  agreement 
with a  previous report from McNew and Goodman (40), 
which showed that  -SKL and  -AKL  were functional as 
PTSs in yeast when appended to the COOH terminus of 
ChAT via a  single glycine residue. The ability of CHAT- 
GSKL (and ChAT-GAKL) to localize to peroxisomes ef- 
fectively rules  out  the  possibility  that  failure  of CHAT- 
GANL  to  be  targeted  is  due  to  the  three-dimensional 
structure of this fusion protein rendering the COOH ter- 
minus  inaccessible  to  the  cellular machinery responsible 
for recognition and import of COOH-terminal PTSs. 
A  Positively Charged Amino Acid Four Residues from 
the COOH Terminus Is an Important Component of 
the Human Catalase PTS 
Having established  the  importance of the  residue  fourth 
from the COOH terminus as part of the  human catalase 
PTS, a more detailed analysis of the permissible amino ac- 
ids  at  this  position  was  conducted.  For  this  purpose,  in 
vitro mutagenesis was used to generate a series of clones 
identical  to pChAT-EKANL (which  encodes  ChAT  ap- 
pended with the last five amino acids of human catalase), 
except with the lysine (underlined) replaced with one of a 
range of other amino acids. Expression of these plasmids 
in 3A cells followed by subcellular fractionation revealed 
that only arginine could replace this lysine without causing 
a major reduction in peroxisomal targeting (Fig. 5 A). Of 
the other amino acids tested in this position, most resulted 
in a dramatic reduction of peroxisomal targeting to levels 
ranging from undetectable to <10% peroxisomal (alanine, 
aspartate,  asparagine,  glycine  and  proline,  methionine, 
and serine). However, other amino acids, such as leucine, 
glutamine, and valine resulted in only a  moderate reduc- 
tion in peroxisomal targeting (Fig. 5 A). Double immuno- 
fluorescence with anti-ChAT and goat anti-catalase A  cor- 
roborated the cellular fractionation data. ChAT-ERANL 
showed strong colocalization with catalase A, consistent with 
efficient targeting of this construct to peroxisomes, whereas 
constructs which showed reduced targeting to the organel- 
lar pellet (such as ChAT-ELANL) also colocalized with cata- 
lase A  to particles, but with a  higher level of anti-ChAT 
cytosolic fluorescence than that seen with ChAT-ERANL, 
and constructs which were absent from the organellar pel- 
let (such as ChAT-EGANL) gave only cytosolic fluores- 
cence (Fig. 5 B). These results suggest that a basic amino 
acid, four residues from the COOH terminus of the human 
catalase COOH terminus, is required to maintain full PTS 
activity, but that a limited number of nonbasic residues at 
this position may also support sub-optimal PTS activity. 
The S. cerevisiae PTS1 Receptor, Pas  l Op, Interacts with 
the COOH Terminus of Human Catalase, and Is 
Required for Human Catalase PTS Function 
Pasl0p, encoded by the PASIO gene, has been identified 
as the S.  cerevisiae PTS1  receptor, partly by virtue of its 
homology to the well-characterized PTS1  receptor of Pi- 
chia pastoris,  Pas8p (64), and partly by demonstration of 
its interaction with  -SKL in the yeast two-hybrid system 
(7). We tested the interaction of Pasl0p with the human 
catalase  PTS.  Cotransformation  of  the  two-hybrid  host 
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genic  chloramphenicol  acetyl 
transferase (CHAT) variants in 
yeast cells, as assessed by immu- 
nofluorescence  and  immunob- 
lotting. (A) 3A cells expressing 
ChAT appended at the COOH- 
terminus  with  either  -KANL 
(3A-pChAT-KANL), -GANL 
(3A-pChAT-GANL),  the  last 
nine residues of human catalase 
(3A-pChAThCAT9),  -ANL 
(3A-pChAT-ANL), or -GSKL 
(3A-pChAT-GSKL), were sub- 
jected to  immunofluorescence 
with  polyclonal  anti-ChAT. 
3A  =  untransformed negative 
control. Bar, 5  p~m. (B)  Post- 
nuclear  supernatant  fractions 
were separated by differential 
centrifugation (61) into organel- 
lar pellets (P), and high speed 
supernatants (S), and subjected 
to  SDS-PAGE  and  immuno- 
blotting. Anti-ChAT was used to detect the various forms of transgenic ChAT (upper portion of figure), followed by anti-catalase A 
(lower portion of figure). (C). Colocalization of ChAT-hCAT9 and catalase A  as revealed by double immunofluorescence of 3A- 
pChAT-hCAT9 with anti-ChAT and anti-catalase A. Bar, 5 txm. 
strain SFY526  with plasmids encoding the  activation do- 
main  of GAL4  fused  to  Pasl0p  (pGAD424-pas10),  and 
the DNA-binding domain of GAL4 fused to the COOH- 
terminal 146 amino acids of normal human catalase (pGBT9- 
hCAT1)  resulted  in  colonies which  synthesized  [3-galac- 
tosidase (Fig. 6), indicating that Pasl0p binds the COOH 
terminus of catalase. Controls lacking either Pasl0p or hu- 
man  catalase  did  not  synthesize  13-galactosidase.  More- 
over,  introduction  of  amino  acid  changes  at  either  the 
penultimate  residue  (asparagine-to-aspartate),  or  four 
Figure  5.  The  fourth  amino 
acid from the COOH terminus 
constitutes a critical component 
of the human catalase PTS, as 
assessed  by  immunoblotting 
and  immunofluorescence.  (A) 
3A  cells  expressing  various 
forms of ChAT-EXANL, where 
X is any of a number of different 
amino acids, were subjected to 
subcellular fractionation. Post- 
nuclear  supernatant  fractions 
were separated by differential 
centrifugation  (61)  into  or- 
ganellar pellets  (P)  and  high 
speed  supernatants  (S),  and 
subjected to  SDS-PAGE  and 
immunoblotting.  Anti-ChAT 
was used to detect the various 
forms of transgenic ChAT (up- 
per portion), followed by anti- 
peroxisomal  thiolase  (lower 
portion).  Quantitative estima- 
tion of the proportion of ChAT 
in  pellets  (and  supernatants) 
was performed using a Molecu- 
lar Diagnostics Personal Den- 
sitometer. (B)  Localization of 
various ChAT constructs and catalase A  as revealed by double immunofluorescence of 3A-pChAT-ERANL (Arg), 3A-pChAT- 
ELANL (Leu), and 3A-pChAT-EGANL (Gly) with anti-ChAT (upper panels) and anti-catalase A (lower panels). Occasional CHAT- 
negative cells can be accounted for by plasmid loss during the YPGO growth of the cells. Bar, 5 Ixm. 
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receptors of yeast and humans in the yeast two-hybrid assay. 
13-galactosidase expression  was determined by immunoblotting 
with anti-~3-galactosidase, using 25 I~g aliquots  of glass-bead ho- 
mogenates. In each case yeast host strain SFY526 had been trans- 
formed  with  two  plasmids.  One  plasmid  contains  the  GAL4 
DNA-binding domain (DB) fused to the last 146 amino acids of 
human catalase with normal COOH-terminal sequence  (CAT) or 
with  this sequence mutated to -KADL (CAT~AI~L) or -GANL 
(CATGANL). The other plasmid contains  the GAL4 transactiva- 
tion domain (TA) fused to either the yeast PASIO gene (PAS10) 
or the cDNA encoding  amino acids 238-639 of the human PTS1 
receptor (PTS1R).  -, vector alone, expressing unmodified  GAL4 
domains. 
residues  from  the  COOH  terminus  (lysine-to-glycine), 
both of which abolish the catalase PTS function, also elim- 
inated the interaction with Pasl0p in the two-hybrid assay 
(Fig. 6), suggesting that it is the PTS itself which is binding 
to Pasl0p. To further test the role of Pasl0p in the func- 
tioning  of  the  human  catalase  PTS,  ChAT-KANL  and 
ChAT-hCAT9 were expressed in yeast strain 3A-ApaslO, 
in  which  the  PASIO gene  had  been  disrupted.  Immuno- 
fluorescence  analysis  revealed  that  ChAT-KANL  (and 
ChAT-hCAT9)  remain  cytosolic  in  these  cells,  whereas 
thiolase (which is targeted by an NH2-terminal PTS2 sig- 
nal) is peroxisomal (Fig. 7). This contrasts with the peroxi- 
somal  location  of  ChAT-KANL  (and  ChAT-hCAT9) 
when expressed in wild-type cells (Fig. 4 A), and confirms 
that the human catalase COOH-terminal PTS does belong 
to the PTS1 family of peroxisomal targeting signals. 
The Identified Human Catalase PTS Is Also Functional 
in Human Cells 
To evaluate whether the  COOH-terminal PTS of human 
catalase that is responsible for targeting in yeast also func- 
tions  in  human  cells,  the  constructs  encoding  CHAT- 
GSKL, ChAT-GANL, ChAT-hCAT9, and ChAT-KANL 
were subcloned into a suitable vector containing the CMV 
promoter  (see  Materials  and  Methods),  and  transfected 
into human fibroblasts. 
Immunofluorescence analysis of the transfected cells re- 
vealed a  pattern  of targeting in  the  human cells entirely 
equivalent to that found in yeast cells. As shown in Fig. 8, 
ChAT-GSKL,  ChAT-KANL,  and  ChAT-hCAT9  were 
routed to peroxisomes, as witnessed by punctate fluores- 
cence  with  anti-ChAT,  whereas  cells  expressing  CHAT- 
GANL  exhibited  fluorescence  throughout  the  cytosol, 
consistent  with failure to import this variant. To test the 
role of the human PTS1 receptor in the functioning of the 
last four amino acids of human catalase as a  PTS, CHAT- 
KANL and  ChAT-hCAT9  were expressed in fibroblasts 
of a  neonatal  adrenoleukodystrophy patient containing a 
missense mutation encoding an  asparagine-to-lysine sub- 
stitution at residue 489 of the PTS1 receptor. This mutation 
Figure 7.  Dependence of human catalase PTS function  upon the 
yeast PTS1 receptor, Pasl0p.  ChAT-KANL and ChAT-hCAT9 
were expressed in 3A-ApaslO cells, which lack Pasl0p, and de- 
tected by immunofluorescence  using anti-ChAT (upper panels). 
Peroxisomes  were detected with anti-thiolase  (lower  panels). All 
of the fluorescent cells in the upper panels show cytosolic fluores- 
cence when viewed while focusing up and down. Bar, 5 I~m. 
abolishes the import of proteins targeted by PTS1 signals, 
whereas  PTS2-targeted  proteins  are  imported  normally 
(16).  Immunofluorescence  analysis  of  this  cell  line  re- 
vealed  a  cytosolic  distribution  of  endogenous  catalase 
(data not shown), in agreement with previously published 
results (44). ChAT-KANL had a cytosolic distribution  in 
these cells, as did ChAT-hCAT9 (Fig. 8). These data show 
that the human catalase PTS requires  a  functional  PTS1 
receptor, and confirm that the particles observed in wild- 
type fibroblasts (Fig. 8) are indeed peroxisomes. In addi- 
tion, human catalase interacted with the human PTS1 re- 
ceptor in  a  yeast two-hybrid assay (Fig. 6).  Altering the 
penultimate residue of catalase from asparagine to aspar- 
tate  abolished  the  interaction,  as  did  changing  lysine  to 
glycine four residues from the COOH terminus. These re- 
sults demonstrate that the human catalase PTS identified 
by the transgenic studies in yeast cells most probably rep- 
resents the genuine PTS of this protein. 
Peroxisomal Import of Fusion Proteins Between Yeast 
Catalase A  and Human Catalase 
A  recent  investigation  of  the  peroxisomal  targeting  of 
yeast catalase A revealed the presence of at least two inde- 
pendent PTSs. The last six residues of catalase A, -SSN- 
SKF, were shown to be sufficient for peroxisomal targeting 
of reporter proteins, but this hexapeptide was dispensable 
for catalase A  targeting due to the existence of a second, 
internal  PTS,  tentatively identified  as  being  located  be- 
tween residues 104-126  (30). The results presented above 
suggest  that  peroxisomal targeting of human  catalase in 
yeast is similar to catalase A  targeting in that  a  COOH- 
terminal PTS is present, but  different in that loss of this 
PTS  abolishes  peroxisomal  targeting.  This  is  somewhat 
surprising given the sequence similarities between the two 
catalases in the region corresponding to the internal cata- 
lase  A  PTS  (see Fig.  9).  In the  light  of this, we  investi- 
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panels) Peroxisomal targeting in normal human cells as assessed 
by immunofluorescence  of normal human fibroblasts  expressing 
ChAT-hCAT9,  ChAT-KANL, ChAT-GANL, and ChAT-GSKL, 
and  mock-transfected fibroblasts  (no DNA,  negative  control). 
(Bottom panel) Dependence  of human  catalase  PTS  function 
upon the human PTS1 receptor. Neonatal adrenoleukodystrophy 
gated the ability of yeast catalase A-human catalase fusion 
proteins to localize to peroxisomes, and the dependence 
of this on the COOH-terminal human catalase PTS. Plas- 
mids encoding fusions consisting of the first 378 residues of 
catalase A  followed by residues 384-527  of either  normal 
human  catalase  (CATA-hCAT,  encoded  by  pCATA- 
hCAT1),  or  catalase  with  the  penultimate  asparagine 
changed  to  aspartate  (CATA-hCATADL,  encoded  by 
pCATA-hCAT4) were constructed  and transformed into 
3A cells. These catalase fusions could be readily detected 
with antibody 10-330 by immunoblotting and immunoelec- 
tron microscopy, but not by immunofluorescence. Immuno- 
electron  microscopic  analysis  demonstrated  that  the 
CATA-hCAT, which  includes  the  intact  human catalase 
COOH terminus, was located principally within the perox- 
isomal  matrix  and,  interestingly,  the  labeling  with  gold 
particles was frequently confined to an electron dense sub- 
compartment of the organelle, suggesting that the catalase 
fusion may be  forming into  intraperoxisomal aggregates 
(Fig. 2 C). 
Mutation of the COOH-terminal PTS of the fusion pro- 
tein by changing the penultimate asparagine to aspartate 
(CATA-hCATAoL) did not abolish its peroxisomal target- 
ing. Immunoelectron microscopy showed that this fusion was 
present in  the  peroxisomal matrix (Fig. 2  D).  Consistent 
with this, cell fractionation revealed that CATA-hCATAo  L, 
in contrast to hCATADL,  was found in the organellar pel- 
let,  although  the  efficiency of targeting  appeared  to  be 
lower than for CATA-hCAT (see Fig. 3). Thus, the inter- 
nal  catalase  A  PTS is  functional  to  some degree in  this 
construct. 
The  possibility that  peroxisomal targeting of the  cata- 
lase  A-human catalase fusions  might involve interaction 
with the biogenesis pathway of endogenous catalase A was 
investigated by expression of these  fusions in  strain  3A- 
ACatA,  which  lacks  catalase.  Cell  fractionation  data  re- 
vealed that  this  disruption  had  no discernible  impact on 
the proportions of the various human catalase constructs 
found in the organellar pellets (Fig. 3). 
Discussion 
In this paper we provide evidence that targeting of human 
catalase to peroxisomes is mediated  by a  novel COOH- 
terminal PTS which consists of four amino acids. Deletion 
of these  last four residues  (KANL), or  alteration  of the 
penultimate  asparagine  to  aspartate,  abolished  localiza- 
tion of human catalase to yeast peroxisomes. By analogy 
with other characterized PTSs, the COOH-terminal loca- 
tion  of the  human  catalase  PTS suggests  that  it  is  most 
likely a member of the class of COOH-terminal tripeptide 
PTSs collectively known as PTS1, and this is supported by 
evidence (discussed below) that this PTS cannot function 
in yeast or human cells in which the PTS1  receptor is ab- 
sent or nonfunctional.  However, this  PTS differs from a 
classical PTS1 in two major respects. 
(NALD) fibroblasts with a missense mutation in the PTS1 recep- 
tor expressing  ChAT-hCAT9 and ChAT-KANL. The antibody 
was anti-ChAT. The very occasional  bright spots in the case of 
ChAT-GANL appear to be on the cell surface. Bar, 10 I~m. 
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Figure 9.  Comparison  of the sequences  of human  catalase and 
yeast catalase A. Regions shown to correspond to PTSs are un- 
derlined. Numbers refer to amino acids and relative to the amino 
terminus. 
The first of these is the absence of a basic residue at the 
penultimate position. The PTS1 consensus sequence for 
mammals defines an absolute requirement for a basic resi- 
due  at  this  position, with  PTS functionality being abol- 
ished in  every instance  of alteration  of the  penultimate 
residue to a nonbasic amino acid, both in vitro (43) and in 
vivo (23). In S. cerevisiae,  variants of this class of PTS pre- 
viously shown to be active include SKL (multifunctional 
protein  [28],  peroxisomal citrate synthase [56],  peroxiso- 
mal  malate  dehydrogenase [36,  58],  peroxisomal malate 
synthase  [27, 38],  and transgenically expressed firefly lu- 
ciferase [24]), SKF (catalase A  [30]), AKL (mutant trans- 
genic chloramphenicol acetyl transferase  [40]), and AKI 
(transgenically  expressed  Candida  tropicalis  multifunc- 
tional protein [1]), all of which have lysine as the penulti- 
mate  residue.  Moreover, mutating  the  COOH-terminal 
AKI of Candida tropicalis multifunctional protein to -AQI 
abolished peroxisomal targeting of this protein in S. cerevi- 
siae.  Similarly, in Hansenula polymorpha, a basic penulti- 
mate residue is a constant feature of identified COOH-ter- 
minal PTS1 signals (15, 26, 47). 
The second unusual feature of the human catalase PTS 
is  that  it is  not  restricted  to  the  COOH-terminal  three 
amino acids. This is shown by the failure of the tripeptide 
-ANL  to function in place of -SKL in  targeting  a  re- 
porter protein, chloramphenicol acetyl transferase (CHAT), 
to  human  or yeast  peroxisomes  when  appended  to  the 
COOH  terminus  via  a  single  glycine  residue  (CHAT- 
GANL).  This  is  not  due  to  ChAT-GANL  assuming  a 
three-dimensional structure which renders the COOH ter- 
minus unavailable for interaction with the PTS1 recogni- 
tion and import machinery, since McNew and Goodman 
(40) have shown that an equivalent construct with the arche- 
typal PTS1, -SKL (ChAT-GSKL) is efficiently imported 
into S. cerevisiae  peroxisomes. We have confirmed this ob- 
servation  in yeast cells  and  extended it to human  cells. 
Moreover, McNew  and  Goodman (40)  have shown that 
the  PTS1  variant  -AKL  can  function  in  this  context 
(ChAT-GAKL) in yeast. Rather, failure of ChAT-GANL 
to localize to peroxisomes can more satisfactorily be ex- 
plained  as  follows:  the  human  catalase  PTS  is  not  re- 
stricted to the COOH-terminal tripeptide. This postulate 
is supported by the finding that ChAT can be directed to 
yeast peroxisomes when the last four residues of human 
catalase  are  appended  to  the  COOH  terminus  (CHAT- 
KANL). This result indicates that the lysine residue four 
amino acids from the COOH terminus constitutes a criti- 
cal  component  of the  human  catalase  PTS,  and  this  is 
borne out by the observation that substitution of this resi- 
due with a variety of different amino acids abolishes, or re- 
duces, peroxisomal targeting. Significantly, the amino acid 
tested which resulted in little or no decrease in targeting 
was arginine. This argues that the critical requirement at 
this position of the human catalase PTS for maximal tar- 
geting activity may be a basic residue. However, the fact 
that significant levels of targeting were also observed with 
nonbasic residues such as glutamine and leucine at this po- 
sition  suggests  that  the  detailed  structure-function rela- 
tionship of this targeting sequence is more complex than 
an absolute requirement for a basic residue at the -4 posi- 
tion. 
In  the  yeast  Pichia pastoris,  disruption  of  the  PAS8 
gene, which  encodes  the  PTS1  receptor  (60),  results  in 
mistargeting of a range of peroxisomal proteins including 
transgenic  luciferase  (terminates  -SKL),  methanol  oxi- 
dase  (terminates  ARF),  and  dihydroxyacetone synthase 
(terminates DKL) (39). The implication is that Pas8p is a 
PTS1 receptor with broad specificity, recognizing a variety 
of COOH-terminal tripeptides, but with a basic residue at 
the  central  position  being  a  consistent  feature.  Homo- 
logues to P. pastoris PAS8 have been identified in S. cere- 
visiae (64), Hansenula polymorpha  (46, 63), and humans 
(16, 21,  68) suggesting that this mechanism of import is 
conserved. Against this body of evidence for a critical role 
of the penultimate basic residue of PTS1 signals, the only 
example of a nonbasic residue being tolerated at this posi- 
tion is AQI (at the COOH terminus of mutant transgeni- 
cally expressed  C.  tropicalis  multifunctional  protein) in 
Candida albicans (1), other than targeting to trypanosomal 
glycosomes, which is uniquely supported by a tremendous 
range  of COOH-terminal  PTSs  (6,  57).  Therefore, the 
identification within human catalase, which ends -KANL, 
of a significantly new PTS1 variant with asparagine (as op- 
posed to a basic amino acid) at the penultimate position, is 
both unexpected and notable. 
That the human catalase COOH-terminal PTS sequence 
is a member of the FTS1 family is borne out by the obser- 
vations that targeting by this sequence is abolished in yeast 
cells in which the PTS1 receptor (Pasl0p) is absent, and 
in human cells in which the PTS1 receptor is mutated. Fur- 
thermore, use  of the  two-hybrid system has  shown  that 
both the yeast Pasl0p and human PTS1 receptor can interact 
with  the  COOH-terminal  sequence  of  normal  catalase 
(ends -KANL), but not with mutated forms (ending -KADL 
or -GANL) which are nonfunctional as PTSs. It remains to 
be seen whether any naturally occurring peroxisomal pro- 
teins in this yeast contain a PTS1 signal with asparagine 
at the penultimate position. The fact that antibodies against 
a synthetic peptide terminating with AKI show only a very 
weak reaction with a single S. cerevisiae  peroxisomal pro- 
tein,  although  this  tripeptide is  active as a  PTS1  in  this 
yeast (2), suggests that the range of PTSls used may be 
more limited than the full spectrum of permissible tripep- 
tides identified by mutagenesis and heterologous expres- 
sion studies. 
Inclusion of human catalase as a PTS1 targeted protein 
raises something of a  conundrum, namely that if a basic 
penultimate residue is not essential, why have not variants 
lacking this feature been previously identified among the 
wide range of characterized PTS1 signals? One intriguing 
possibility is that the residue (lysine) immediately adjacent 
to the -ANL  terminus which, as described above, forms 
part of the PTS, is critically involved in compensating for 
the lack of a basic penultimate amino acid. Significantly, 
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other  unconventional  mammalian  PTS1  variant,  namely 
the COOH-terminal -KKL signal of human alanine:glyox- 
ylate aminotransferase (AGT) (45).  Like the  -ANL  ter- 
minus of catalase, this tripeptide differs from the mamma- 
lian  PTS1  consensus  at  one  of  the  three  residues,  the 
deviation in this case being a  lysine residue  three amino 
acids from the COOH terminus, as opposed to serine or 
alanine. Also in common with the catalase tripeptide is the 
observation that  the  -KKL is  necessary for peroxisomal 
targeting (of AGT), but is not sufficient to functionally re- 
place  -SKL  as  a  PTS for chloramphenicol  acetyl trans- 
ferase. This has led to the suggestion that some other re- 
gion of AGT is required for functional expression of the 
COOH-terminal targeting sequence  (45).  Thus, although 
it must be borne in mind that this proposed ancillary se- 
quence of AGT remains ill-defined, these results appear 
to suggest  that  targeting of AGT, like catalase,  may in- 
volve additional amino acids which somehow compensate 
for the existence of nonconsensus COOH-terminal PTS1 
signals. Likewise, it may be that more conventional PTS1 
signals are similarly modulated by adjacent sequences. For 
instance, in vitro peroxisomal import of a truncated (non- 
import  competent)  form  of catalase  is  supported  much 
more efficiently by addition of the last five amino acids of 
rat acyl-CoA oxidase (-LQSKL) than by -SKL alone, and 
inhibition of in vitro peroxisomal import of rat acyl-CoA 
oxidase with synthetic peptides has been shown to be much 
more effective with a peptide corresponding to the last 10 
residues of rat acyl-CoA oxidase (-KHLKPLQSKL) than 
with an -SKL tripeptide (43). In addition, chlorampheni- 
col acetyl transferase appended with -AKI has been men- 
tioned  as failing to localize  to peroxisomes, despite  evi- 
dence that -AKI can function as a yeast PTS1 (1). 
Alteration  of  the  internal  -SHL-  tripeptide  near  the 
COOH terminus of human catalase to -TQV- did not pre- 
vent targeting to yeast peroxisomes, effectively ruling out 
this  tripeptide  as  a  novel  "internal  PTSI"  targeting  se- 
quence. Interest in this tripeptide was aroused by the dem- 
onstration that the last 27 residues of human catalase were 
sufficient for targeting to peroxisomes in mammalian cells 
despite the fact that the terminal -ANL  sequence is out- 
side the defined consensus for mammalian PTS1  signals, 
whereas  SHL is within  this consensus  (23,  25).  As such, 
this  internal  SHL  tripeptide  has  represented  the  most 
likely of a  number  of internal  tripeptides  speculated  to 
function  in peroxisomal targeting.  The observations that 
an addition of a single serine residue to the COOH termi- 
nus of luciferase abolished its peroxisomal localization in 
mammalian cells (23), and that inhibition of in vitro perox- 
isome  import with  synthetic  SKL-containing  peptides  is 
only observed if the SKL is at the extreme COOH termi- 
nus of the peptide (43), had indicated that COOH-termi- 
nal PTSs were rendered inactive when moved from the ex- 
treme COOH terminus.  In addition,  it has recently been 
demonstrated  that  an  internal  SKL tripeptide  is  not  in- 
volved in the targeting of the peroxisomal membrane pro- 
tein PMP47 in Candida boidinii (37). Combined with these 
observations, our finding that the internal SHL of human 
catalase is not a PTS now suggests that it is unlikely that 
the PTS1 family of targeting sequences will include inter- 
nal tripeptides. 
Comparison of the results of the mutagenesis of the ex- 
treme COOH terminus of human catalase with similar ex- 
periments using yeast catalase A  reveals both similarities 
and differences. Like human catalase, catalase A  appears 
to have a  COOH-terminal PTS1  (-SSNSKF)  (30).  How- 
ever, deletion of this signal does not prevent targeting of 
catalase A  to peroxisomes, due to the presence of a  sec- 
ond, independent  targeting sequence internal to the pro- 
tein. Clearly, this second PTS is not conserved (in terms of 
functionality in yeast) in the  human protein,  despite the 
fact that a preliminary delineation has identified the inter- 
nal PTS as being between residues  104-126  of catalase A 
(30),  a  region  which  shows  substantial  conservation  be- 
tween yeast and humans.  Consistent with these data, we 
have shown that hybrid catalases, of which approximately 
the NH2-terminal three-quarters is derived from yeast cat- 
alase A, and the remainder from human catalase, can be 
targeted to yeast peroxisomes whether the human COOH- 
terminal PTS is intact (-ANL) or disrupted (-ADL). 
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